Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial.

Imfinzi (durvalumab) - AstraZeneca

Imjudo (tremelimumab-actl) - AstraZeneca

sorafenib - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/42723778

Dong Li; Huixian Jia; Liman Huo; Ping Liang; Qi Lv; Rui Feng; Yajing Wang; Ying Zheng

Sep 12, 2026